Menu
← Oncology Approval Tracker
FDA DECISION ·
Rybrevant
amivantamab-vmjw · Janssen Biotech
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations on an FDA-approved test, after progression during or after platinum chemotherapy.
LAMPGEN ANALYSIS
Why it matters
The accelerated decision adds a targeted antibody in post-platinum EGFR exon 20 insertion disease. FDA later converted the indication on March 1, 2024.
What research teams should watch
Capture the exact insertion class and platinum history and plan monitoring for infusion reactions.
PRIMARY RECORDS